Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically...
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically...
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative...
Four dose cohorts (12, 24, 36 and 54 mg/m2/day) completed (16 patients, 8 with acute leukemia with MLL-r) with 21-day on/7-day off administration...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.